Other Events ·
AbbVie has settled litigation with all generic manufacturers seeking to launch generic versions of its upadacitinib…
ABBVAbbVie Inc.
AbbVie has settled litigation with all generic manufacturers seeking to launch generic versions of its upadacitinib tablets, marketed as RINVOQ. Assuming pediatric exclusivity is granted, the company expects no generic entry for the drug in the United States prior to April 2037. This settlement is significant for investors as it provides long-term revenue protection by extending the market exclusivity of a key product.